Q2 2026 Enovis Corp Earnings Call Transcript

Aug 6, 2026 / 12:30 PM GMT

Release Date Price: $26.31 (-12.82%)

Transcript 10-Q8-K

Key Points

Positve

Enovis Corp (ENOV) delivered 5% organic growth in Q2 2026, with US recon growing 6% and hips/knees up 8%.
Strong innovation momentum: Nebula, ARG, and Avis are gaining traction, with Avis now in full commercial launch and over 80% of new instrumentation sets going to competitive users.
Adjusted gross margins improved by 120 basis points underlying, driven by productivity and mix, despite tariff and inflationary headwinds.
Free cash flow turned positive in the first half, improving by $27 million year-over-year, with leverage down to 3.1x.
Management reaffirmed 2026 guidance and expressed confidence in accelerating growth in Q4, supported by new product launches and commercial execution.
The company is seeing meaningful market share gains in PNR, particularly in bone healing and recovery sciences, with new products like Revital expected to contribute later in the year.

Negative

Organic growth in PNR was only 3%, with international markets negatively impacted by the Middle East conflict, creating a 100 basis point headwind.
The company faces $10 million of full-year inflationary pressure from raw materials and freight, partially offsetting tariff refund benefits.
Q3 is expected to be seasonally softer than prior years due to market conditions in Western Europe and continued Middle East disruption.
US extremities growth was softer in Q2 due to tough comps from the ARG launch and MedEd events taking surgeons out of the field.
The company struggles to pass through price increases in PNR due to competitive dynamics, limiting margin protection.
Management noted potential risks from Western European market softness (France, Spain, Italy) and the possibility of healthcare funding reallocation toward military spending.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ENOV.N - Enovis Corporation
Q2 2026 Enovis Corp Earnings Call
Aug 06, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, and thank you for standing by.

Ladies and gentlemen, welcome to Enova second quarter 2026 earnings call.

Please note that this call is being recorded.

At this time, all participants are in listen-only mode.

There will be some opening remarks followed by a question-and-answer session.

If you wish to ask a question, please press star one on your telephone keypad.

Thank you, I'd now like to turn the call over to Kyle Rose, Vice President investor rela.

Good morning everyone, and thank you for joining us today for our second quarter 2026 earnings conference call.

I'm Kyle Rose, Vice President of Investor Relations.

Joining me on the call this morning are

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.